Krystal Biotech, Inc. Financing Cash Flow
Krystal Biotech, Inc. (KRYS) reported Financing Cash Flow of $4.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- Krystal Biotech, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $15.05M, a 738.14% increase year-over-year.
- Krystal Biotech, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$10.46M.
- Krystal Biotech, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $15.67M, a 545.22% increase year-over-year.
- Krystal Biotech, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.71M, a 10.22% increase year-over-year.
- Krystal Biotech, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $8.71M, a 67.78% decline from fiscal 2024.
- Krystal Biotech, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $27.01M, a 86.68% decline from fiscal 2023.
- Krystal Biotech, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $202.75M, a 473.60% increase from fiscal 2022.
- Krystal Biotech, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $35.35M, a 89.83% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $4.59M 10-Q · filed 2026-08-03 | $20.26M derived: sum of 3 quarters · filed 2026-08-03 | $23.97M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$10.46M 10-Q · filed 2026-05-04 | $5.21M derived: sum of 2 quarters · filed 2026-05-04 | $8.92M derived: sum of 3 quarters · filed 2026-05-04 | $10.71M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $15.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $19.38M derived: sum of 2 quarters · filed 2026-02-17 | $21.17M derived: sum of 3 quarters · filed 2026-08-03 | $8.71M 10-K · filed 2026-02-17 |
| 2025-09-30 | $3.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $5.50M derived: sum of 2 quarters · filed 2026-08-03 | -$6.96M 10-Q · filed 2025-11-03 | -$4.53M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$10.67M 10-Q · filed 2026-08-03 | -$8.24M derived: sum of 3 quarters · filed 2026-08-03 | -$4.88M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$12.47M 10-Q · filed 2026-05-04 | -$10.04M derived: sum of 2 quarters · filed 2026-05-04 | -$6.67M derived: sum of 3 quarters · filed 2026-05-04 | $3.96M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $5.79M derived: sum of 2 quarters · filed 2026-02-17 | $16.43M derived: sum of 3 quarters · filed 2026-02-17 | $27.01M 10-K · filed 2026-02-17 |
| 2024-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $14.00M derived: sum of 2 quarters · filed 2025-11-03 | $24.59M 10-Q · filed 2025-11-03 | $27.20M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $10.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $21.22M 10-Q · filed 2025-08-04 | $23.84M derived: sum of 3 quarters · filed 2026-02-17 | $37.23M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $10.58M 10-Q · filed 2025-05-06 | $13.20M derived: sum of 2 quarters · filed 2026-02-17 | $26.59M derived: sum of 3 quarters · filed 2026-02-17 | $211.86M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $16.01M derived: sum of 2 quarters · filed 2026-02-17 | $201.28M derived: sum of 3 quarters · filed 2026-02-17 | $202.75M 10-K · filed 2026-02-17 |
| 2023-09-30 | $13.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $198.66M derived: sum of 2 quarters · filed 2024-11-04 | $200.13M 10-Q · filed 2024-11-04 | $203.20M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $185.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $186.74M 10-Q · filed 2024-08-05 | $189.81M derived: sum of 3 quarters · filed 2025-02-19 | $191.93M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $1.47M 10-Q · filed 2024-05-06 | $4.54M derived: sum of 2 quarters · filed 2025-02-19 | $6.66M derived: sum of 3 quarters · filed 2025-02-19 | $37.36M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $5.19M derived: sum of 2 quarters · filed 2025-02-19 | $35.89M derived: sum of 3 quarters · filed 2025-02-19 | $35.35M 10-K · filed 2025-02-19 |
| 2022-09-30 | $2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $32.82M derived: sum of 2 quarters · filed 2023-11-06 | $32.28M 10-Q · filed 2023-11-06 | $234.35M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $30.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $30.16M 10-Q · filed 2023-08-07 | $232.23M derived: sum of 3 quarters · filed 2024-02-26 | $233.74M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$542.00K 10-Q · filed 2023-05-08 | $201.53M derived: sum of 2 quarters · filed 2024-02-26 | $203.04M derived: sum of 3 quarters · filed 2024-02-26 | $202.84M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $202.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $203.58M derived: sum of 2 quarters · filed 2024-02-26 | $203.38M derived: sum of 3 quarters · filed 2024-02-26 | $347.69M 10-K · filed 2024-02-26 |
| 2021-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.31M derived: sum of 2 quarters · filed 2022-11-07 | $145.61M 10-Q · filed 2022-11-07 | $145.75M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$199.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $144.10M 10-Q · filed 2022-08-08 | $144.25M derived: sum of 3 quarters · filed 2023-02-27 | $144.41M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $144.30M 10-Q · filed 2022-05-09 | $144.44M derived: sum of 2 quarters · filed 2023-02-27 | $144.61M derived: sum of 3 quarters · filed 2023-02-27 | $262.08M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $307.00K derived: sum of 2 quarters · filed 2023-02-27 | $117.78M derived: sum of 3 quarters · filed 2023-02-27 | $118.02M 10-K · filed 2023-02-27 |
| 2020-09-30 | $166.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $117.64M derived: sum of 2 quarters · filed 2021-11-08 | $117.88M 10-Q · filed 2021-11-08 | $118.18M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $117.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $117.71M 10-Q · filed 2021-08-09 | $118.01M derived: sum of 3 quarters · filed 2021-08-09 | $131.18M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $243.00K 10-Q · filed 2021-05-10 | $542.00K derived: sum of 2 quarters · filed 2021-05-10 | $13.71M derived: sum of 3 quarters · filed 2021-05-10 | $107.73M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $299.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $13.47M derived: sum of 2 quarters · filed 2021-03-01 | $107.48M derived: sum of 3 quarters · filed 2021-03-01 | $107.53M 10-K · filed 2021-03-01 |
| 2019-09-30 | $13.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $107.19M derived: sum of 2 quarters · filed 2020-11-09 | $107.23M 10-Q · filed 2020-11-09 | $171.51M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $94.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $94.06M 10-Q · filed 2020-08-07 | $158.35M derived: sum of 3 quarters · filed 2020-08-07 | $167.90M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $40.00K 10-Q · filed 2020-05-04 | $64.33M derived: sum of 2 quarters · filed 2020-05-04 | $73.88M derived: sum of 3 quarters · filed 2020-05-04 | $73.88M derived: sum of 4 quarters · filed 2020-05-04 |
| 2018-12-31 | $64.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $73.84M derived: sum of 2 quarters · filed 2020-03-10 | $73.84M derived: sum of 3 quarters · filed 2020-03-10 | $73.85M 10-K · filed 2020-03-10 |
| 2018-09-30 | $9.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $9.55M derived: sum of 2 quarters · filed 2019-11-04 | $9.56M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $10.00K 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $6.00K 10-Q · filed 2019-05-07 | |||
| 2017-09-30 | $50.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $52.46M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $2.30M 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |